UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
September 25, 2017
Hoverink Biotechnologies Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware 000-54830 46-3590875
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1801 Century Park E., 24th Floor
Los Angeles, California
90067
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code:
866-443-4666
Former name or former address, if changed since last report:
Hoverink International Holdings, Inc.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
1
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
2
ITEM 1.01 Entry into a Material Definitive Agreement
On September 22, 2017 we borrowed $115,060 pursuant to an unsecured loan agreement with Cyrus Sajna.
Item 9.01 Financial Statement and Exhibits
(d) Exhibits
Exhibit No.
Description
9.1
Loan Agreement with Cyrus Sajna
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Hoverink Biotechnologies, Inc.
Date: September 25, 2017
Debbie Mae Carter
Chief Executive Officer
4
LOAN
(Principal and Interest at Maturity)
In consideration of value received, the undersigned (hereinafter "Hoverink Biotechnologies, Inc. Borrower") does hereby promise to pay to w. Cyrus Sajna (hereinafter "Lender"), the amount of $115,060 upon which interest will accrue at 0 percent per annum. Borrower agrees to pay all accrued interest plus principal on the 22nd day of Sept 2022. Any payments shall be first applied to interest and then to the principal. This loan may be paid in full at any time without penalty charges.
In the event this Loan shall be in default, and collection proceedings are instituted, then the Borrower does so agree to pay all reasonable attorney fees and costs of collection.
The undersigned and all other parties to this loan, whether as endorsers, guarantors or sureties waive demand, presentment and protest and all notices thereto and further agree to remain bound, notwithstanding any extension, modification, waiver, or other indulgence by any holder or upon the discharge or release of any obligor hereunder or to this loan, or upon the exchange, substitution, or release of any collateral granted as security for this Note.
_____________________________
________
Debbie Mae Carter
Hoverink Biotechnologies, Inc
Borrower
Date
_____________________________
________
Cyrus Sajna
Lender
Date